Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

TRICITY PAIN ASSOCIATES PA

NPI: 1619244720 · SAN ANTONIO, TX 78258 · Anesthesiology Physician · NPI assigned 11/18/2011

$485K
Total Medicaid Paid
15,028
Total Claims
13,854
Beneficiaries
27
Codes Billed
2021-05
First Month
2024-12
Last Month

Provider Details

Authorized OfficialEFIRD, KENNETH (COO)
NPI Enumeration Date11/18/2011

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2021 615 $11K
2022 4,658 $121K
2023 7,691 $235K
2024 2,064 $117K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 7,985 7,343 $364K
64483 384 318 $50K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 1,128 1,067 $36K
80305 2,175 2,043 $9K
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 142 137 $6K
20553 504 452 $6K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 499 484 $4K
62321 20 12 $1K
64493 16 12 $1K
99203 Office or other outpatient visit for the evaluation and management of a new patient, low complexity 23 23 $1K
J1030 Injection, methylprednisolone acetate, 40 mg 548 494 $1K
76942 116 111 $938.45
80336 56 56 $930.80
80332 56 56 $908.44
80338 56 56 $585.00
64494 16 12 $541.30
J1040 Injection, methylprednisolone acetate, 80 mg 86 76 $475.99
80355 59 59 $445.50
80366 57 57 $385.84
J1885 Injection, ketorolac tromethamine, per 15 mg 506 453 $344.55
99442 28 28 $321.40
J1100 Injection, dexamethasone sodium phosphate, 1 mg 426 374 $260.31
J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg 34 29 $90.96
99072 21 18 $0.00
Q9966 Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml 14 12 $0.00
99441 21 20 $0.00
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 52 52 $0.00